Clinical Trials Directory

Trials / Completed

CompletedNCT01503112

Predicting Response to Incretin Based Agents in Type 2 Diabetes

Does Urinary C-peptide Creatinine Ratio Predict Response to Incretin Based Agents in Type 2 Diabetes

Status
Completed
Phase
Study type
Observational
Enrollment
957 (actual)
Sponsor
Royal Devon and Exeter NHS Foundation Trust · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

Type 2 diabetes is a major and rapidly increasing health problem worldwide. Keeping the blood glucose (sugar) from going too high helps prevent complications. Recently a number of new treatments (collectively called 'incretin based' treatments) to lower blood glucose have become available but response is very variable and it is difficult to predict which will work for an individual. The investigators want to see if we can identify whether the new treatments are likely to be effective for an individual patient. Identifying the right treatment would improve control and minimise the side-effects and costs from ineffective treatments. We will collect blood (for measures of blood glucose, insulin secretion and genetics information), urine (for a simple measurement of insulin secretion) and other clinical information (such as weight,age, duration of diabetes and medication) in people who are about to start these new 'incretin based' treatments and assess their response over the first 6 months of treatment. We will analyse this information to see if we can predict treatment response. Study Hypothesis: The investigators hypothesise that those who have low insulin secretion, as measured by post meal urine C-peptide Creatinine Ratio or blood C-peptide, will have poor blood glucose response to incretin based treatments.

Conditions

Interventions

TypeNameDescription
OTHERNo intervention, observational study

Timeline

Start date
2011-05-01
Primary completion
2014-04-01
Completion
2014-04-01
First posted
2012-01-02
Last updated
2018-04-19

Locations

18 sites across 1 country: United Kingdom

Source: ClinicalTrials.gov record NCT01503112. Inclusion in this directory is not an endorsement.